Propanc Biopharma Inc(PPCB) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 3 at 4:55 PM ET (Korea 11/4 06:55)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -258.08 | Insider Own | - | Shs Outstand | 0.3M | Perf Week | -29.63% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | - | Perf Month | -65.8% |
| Enterprise Value | 0.00B | PEG | - | EPS next Q | - | Inst Own | 0.46% | Short Float | - | Perf Quarter | -85.51% |
| Income | -0.02B | P/S | - | EPS this Y | - | Inst Trans | - | Short Ratio | 0.03 | Perf Half Y | -93.34% |
| Sales | 0.00B | P/B | 0.06 | EPS next 5Y | - | ROA | -116.39% | Short Interest | 0.01M | Perf YTD | -98.73% |
| Book/sh | 28.4 | P/C | 2.13 | EPS past 3/5Y | 98.13% 97.29% | ROE | -161.86% | 52W High | -99.46% ($315.00) | Perf Year | -99.39% |
| Cash/sh | 0.8 | P/FCF | - | Sales past 3/5Y | - | ROIC | -200.12% | 52W Low | -0.58% ($1.72) | Perf 3Y | -100% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 98.74% | Gross Margin | - | Volatility(W/M) | 13.94% 13% | Perf 5Y | -100% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.55 | Perf 10Y | -100% |
| Dividend Ex-Date | - | Quick Ratio | 2.55 | EPS Q/Q | 84.24% | Profit Margin | - | RSI (14) | 20.49 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.55 | Sales Q/Q | - | SMA20 | -45.59% ($3.14) | Beta | 3.32 | Target Price | $380 |
| Payout | - | Debt/Eq | 0.05 | Earnings | - | SMA50 | -73.04% ($6.34) | Rel Volume | 0.16 | Prev Close | $1.72 |
| Employees | 2 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -92.44% ($22.62) | Avg Volume(3M) | 0.19M | Price | $1.71 |
| IPO | 2012/11/12 | Option/Short | No/Yes | Trades | 241 | Volume | 29,652 | Change | -0.58% |
A pancreatic, ovarian, and colorectal cancer drug developer based in Australia, this biopharmaceutical company is developing PRP, an intravenous proenzyme-based therapy.
Over the past 1 year, on the lower side
99% below its 1-year high.
Traded less than usual. That is 16% of its average volume.
PPCB has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -100.0%. The S&P 500 did +62% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 0.5%.
Tap to view numbers
It ranks #581 of 597 in the industry
Based on market cap of $2M.
PPBT#579 Purple Biotech Ltd ADR $2M PER - 
XRTX#580 XORTX Therapeutics Inc $2M PER - PPCB#581 Propanc Biopharma Inc $2M PER - 
KAPA#582 Kairos Pharma Ltd $2M PER - 
OGEN#583 Oragenics Inc $2M PER - 
FAQ
What kind of company is PPCB?
PPCB belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of PPCB?
The market cap of PPCB is approximately $2M, ranking 5,817 within its sector.
What is the 52-week high and low for PPCB?
PPCB has recorded a 52-week high of $315.00 and a low of $1.72.
